Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 73,73 € (-2,28 %). La mediana es de 95,80 € (+26,97 %).
| Comprar |
8 |
| Mantener |
15 |
| Vender |
2 |
Noticias Ir al feed de noticias
Agilon Health significantly beats Q2 expectations and raises full‑year outlook
Agilon Health reported adjusted earnings of $1.04 per share in Q2 2026 (expectation $0.08) and revenue of $1.49 billion (expectation $1.44 billion), and subsequently raised its full‑year guidance for revenue, medical margin and adjusted EBITDA. The medical margin rose to $197 million and adjusted EBITDA to $70 million, despite a deliberate 12.3% reduction in Medicare Advantage membership. Management attributes the strong results to stricter contract discipline, improved risk adjustments and favorable cost trends. The stock jumped sharply and the company now expects about $5.8 billion in revenue and roughly $85 million of adjusted EBITDA for 2026. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | |
|---|---|---|
| Ingresos | 1309,71 M | 10,66 % |
| Beneficio bruto | 93,88 M | 311,05 % |
| Beneficio neto | 15,73 M | 117,77 % |
| EBITDA | 9,83 M | 112,14 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1257,16 M € |
Número de acciones | 16,68 M |
Máximo/mínimo de 52 semanas | 114,82 € - 6,46 € |
| Dividendos | No |
Beta | 3,05 |
Ratio P/E | -5,68 |
Ratio PEG | -1,46 |
Ratio P/B | 6,41 |
Ratio P/S | 0,25 |
Perfil de la empresa
| Nombre | Agilon Health Inc |
| CEO | Timothy O'Rourke |
| Empleados | 856 |
Deep Dive
Descubrir activos
Los accionistas de Agilon Health Inc también invierten en los siguientes activos
